Date: 07 July 2014
Description: A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals of the new antibody persistence data for MencevaxACWY™. The immunity to serogroups W-135 and Y in individuals 11-55 years of age who were vaccinated two years earlier with MencevaxACWY™ is 24.0% and 44.0%, respectively. Limited data showed a waning of serum bactericidal antibody titres against serogroupA one year post-vaccination when using human complement in the assay (hSBA). Individuals remaining at high risk of exposure to serogroups A, W-135 and Y should be considered for earlier revaccination according to local recommendations. The package insert for MencevaxACWY™ will be updated by Glaxo SmithKline Pharmaceuticals (Malaysia) Sdn. Bhd. to reflect this new persistence data. Please refer to the DHPC for further information.